U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284901) titled 'Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes' on Dec. 09.
Brief Summary: The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on:
* Percent change in body weight
* Change in hemoglobin A1c (HbA1c)
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Obesity With Diabetes
Overweight With Diabetes
Intervention:
DRUG: KAI-9531
SC Injection
DRUG: Placebo
SC Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kailera
Published by HT Digital Content Servi...